Outcome of the Board Meeting held on 30.05.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.7 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025, with statutory auditor Pavuluri & Co. issuing an unmodified (unqualified) opinion. On a standalone basis, full-year revenue from operations rose to ₹4,360.99 lakh from ₹3,850.17 lakh (about 13% growth), and the company swung to a profit after tax of ₹73.57 lakh versus a loss of ₹104.96 lakh in FY24. However, the standalone Q4 numbers showed a loss of ₹133.71 lakh, indicating weakness in the closing quarter. On a consolidated basis, revenue grew to ₹4,684.36 lakh from ₹3,965.04 lakh, with a thin profit of ₹5.90 lakh versus a ₹132.72 lakh loss last year. The board also appointed M/s KP & Associates as internal auditors for FY26 and M/s Aakanksha Dubey & Co. as secretarial auditors for five years (FY26–FY30). Additionally, Chief Operating Officer Chakrapani Majumdar resigned with immediate effect citing personal commitments.
The FY25 results mark a return to profitability after a loss in FY24, which is a positive signal for shareholders, but the Q4 standalone loss and razor-thin consolidated profit suggest the recovery is fragile. The COO resignation is a management-level change worth monitoring, while the auditor appointments are routine governance matters.